This study reviews important nutrients responsible for oxidant-antioxidant balance in trauma patients requiring admission to the ICU and rationale for repletion of antioxidants using pharmaconutrition.
INTRODUCTION
Severely injured patients requiring admission to the ICU suffer from oxidative stress in which hypoperfusion, reperfusion, endothelial injury, and systemic activation of the immune response result in (or worsen) their critical illness [1] . The underlying pathophysiology of oxidative stress is cytokine release and systemic inflammation triggered by reactive oxygen and nitrogen-oxygen species, which leads to mitochondrial dysfunction, tissue injury, organ failure, and death [1] [2] [3] [4] .
Antioxidants (AOXs) are enzymes such as superoxide dismutase, catalase, and glutathione that catalyze the breakdown of reactive oxygen species. Co-factors required for AOX function include selenium, zinc, manganese, iron, and vitamins C and E [5, 6] . Studies have demonstrated belownormal plasma levels of vitamin C, glutathione, and zinc in severely injured and critically ill patients [7] . Low levels of selenium are inversely related to the degree of systemic inflammation. Since AOXs are depleted after major trauma, sepsis or respiratory failure, their replacement and the restoration of oxidant-antioxidant balance decreases organ dysfunction. Therefore, a decrease in ICU and hospital length of stay (LOS), as well as mortality, seems to be a rational hypothesis and reasonable expectation [6, 8] .
A paradigm shift has occurred transitioning the concept of immunonutrition or immuneenhancing diets to pharmaconutrition in which administration of nutrients, including AOX and co-factors, is disease-specific and dosed separately from standard nutritional requirements [4, 9] . The shift to pharmaconutrition changes the view of nutrition from adjunctive supportive care to active therapeutic strategy to support cellular defense, decrease oxidative stress, and attenuate the systemic inflammatory response to improve the outcome in severely injured and critically ill patients [4, 10, 11] .
The goal of this review, though by no means exhaustive, serves to highlight recent data regarding AOX use in the trauma setting and outcomes in critically ill patients. Whereas the majority of research has been conducted in nontrauma but critically ill populations, these studies are highly relevant and important to those caring for the seriously injured patients and their findings applicable to trauma patients requiring ICU admission.
GLUTAMINE
Glutamine plays a central role in nitrogen transport, intestinal mucosal integrity, nucleotide and arginine synthesis, and renal angiogenesis [4, 5] . It is the preferred nutrient of enterocytes and is preferentially absorbed over glucose in instances of gut ischemia. Glutamine from muscle acts as a stress signal in sepsis and shock and is important for gene activation to promote cellular protection and immune regulation. Glutamine acts as an AOX by enhancing glutathione levels [7, 10, 12] . In critical illness, glutamine is a conditionally essential nutrient where demand exceeds synthesis or stores from proteolysis. A decrease in supplies of glutamine is associated with immune dysfunction and increased mortality [4] .
Studies have shown that glutamine delivered via the parenteral route has been associated with decreased length of mechanical ventilation, decreased risk of pneumonia, and decreased bacteremia and fungemia incidence [5, 13] . Interestingly, however, these reductions in severity of illness and complications have not consistently been associated with decreased ICU or hospital LOS. Jones and Heyland [4] have demonstrated that glutamine confers a protective effect against insulin resistance, thereby aiding in achieving control in the ICU. The route of administration, however, remains controversial. Whereas equivocal data exist for enteral administration of glutamine, parenteral administration to critically ill patients is a grade A recommendation. In fact, when administered intravenously, glutamine has been noted to aid in prevention and treatment of multiorgan dysfunction syndrome (MODS) after sepsis and critical illness [13, 14] . Weitzel et al. [11] advocate for the use of high-dose parenteral glutamine, with doses greater than 0.35 g/kg/day in ICU patients [11, 14] . Finally, preoperative infusion of glutamine has been shown to reduce muscle cell damage and enhance AOX capacity via elevation of glutathione levels in patients with critical limb ischemia [15 & ]. Glutamine may thereby serve to reduce oxidative stress in patients undergoing lower limb bypass surgery for critical limb ischemia.
ARGININE
Arginine is also a conditionally essential nutrient obtained from dietary or endogenous sources via the urea cycle [5] . Arginine serves as a stimulant to release growth factor, prolactin, and insulin and enhances T-cell function. It plays a role in collagen synthesis and production of somatostatin and glucagon [4, 6] . L-arginine in particular is an important substrate for nitric oxide production [5] . During oxidative stress, decreased levels of arginine are present as a result of decreased dietary uptake and increased metabolism via nitric oxide synthetase to create nitric oxide compounds or arginase to create urea and ornithine. Depleted levels of arginine lead to decreased T-cell function and increased risk of infection, making arginine supplementation appear to be a worthwhile adjunct in states of oxidative stress [4] . However, inducible nitric oxide synthetase is up-regulated in inflammatory states leading to an increased production of nitric oxide with a potential increased mortality rate associated with arginine supplementation in patients with septic shock.
Gough et al. [16] compared 109 severe sepsis patients to 50 control patients, assessing their systemic arginine availability by measuring its ratio to symmetric and asymmetric dimethylarginine (endogenous arginine inhibitors). In this
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prospective cohort study, a lower ratio of arginine to dimethylarginine was associated with severe sepsis, increased severity of illness and worse clinical outcome. The ratio also independently predicted hospital mortality and risk of death over a 6-month time period. The utility of the arginine to dimethylarginine ratio may be useful as a biomarker with the potential to augment systemic availability of arginine via supplementation in patients with severe sepsis.
SELENIUM
Selenium is an essential nutrient that serves as a co-factor for glutathione. A decline in plasma glutathione peroxidase activity correlates directly with decreased plasma selenium levels [1, 6] . Selenium supplementation is thought to improve clinical outcomes in critical illness by decreasing infectious complications and organ dysfunction particularly in septic patients [13] . Forceville et al. [17] performed a randomized, double-blind, placebo-controlled trial in which the treatment group received high-dose selenium for a 10-day course (4000 mcg bolus followed by 1000 mcg/day infusion for 9 days). However, there was no significant difference in vasopressor withdrawal, duration of mechanical ventilation, ICU or hospital LOS or mortality between placebo and treatment groups. Manzanares et al. [18] built on this, conducting a study demonstrating that high-dose selenium supplementation (bolus of 2000 mcg of selenite followed by 1600 mcg/day continuous infusion for 10 days) provided the dose most likely to restore serum selenium to physiologic levels and safely maximizing glutathione peroxidase activity in critically ill patients [18, 19] . This group of investigators then conducted a prospective, placebo-controlled, randomized, single-blinded phase II study involving 31 patients. The authors noted that such a regimen decreased mean Sequential Organ Failure Assessment (SOFA) scores, hospital-acquired pneumonia, and early ventilator-associated pneumonia compared with
] conducted a prospective, randomized, single-center clinical trial involving 150 critically ill patients with either systemic inflammatory response syndrome (SIRS) or sepsis and evidence of organ failure or dysfunction. Patients were randomized to receive high-dose selenium supplementation (1000 mcg of sodium selenite on day 1 followed by 500 mcg daily for a total course of 14 days) or placebo. While this study aimed to prove that high-dose selenium would increase plasma selenium levels, decrease severity of disease, reduce markers of inflammation, improve nutritional and AOX defenses, and decrease mortality, no significant differences were noted between treatment and placebo groups.
In a multicenter trial from Germany, however, Angstwurm et al. [22] found that high-dose sodium selenite reduced mortality in patients with severe sepsis or septic shock. The investigators randomized 249 patients in 11 German ICUs to receive either placebo or selenium (1000 mcg of sodium selenite bolus, followed by 14 daily continuous infusions of 1000 mcg). The authors noted that 28-day mortality was significantly reduced in the selenium group (42% compared to 57% in placebo). From a mechanistic standpoint, the investigators demonstrated that selenium concentrations and glutathione peroxidase-3 activity remained normal during selenium treatment, whereas they were significantly decreased in the placebo group.
ZINC
Zinc plays an important role in immune function, glucose control, wound healing, superoxide dismutase and glutathione activity, and thiol pool stabilization [7, 13] . Common clinical manifestations of zinc deficiency include a rash typically seen on the face and gluteal areas, glucose intolerance, abnormal homeostasis, hair loss, altered taste and smell perception, and diarrhea [23 & ]. Low zinc levels have been linked with immune dysfunction, higher infection rates and increased morbidity and mortality after infection especially in the elderly population and patients with chronic illness. Not surprising, zinc supplementation has also been reported to reduce the duration of pneumonia ] performed an observational study demonstrating that serum zinc levels are inversely proportional to SOFA scores and organ failure. Similarly, critical illness, sepsis, and inflammatory states lead to a decline in serum zinc concentrations adding to the belief that zinc supplementation may be beneficial in critical illness. Besecker et al. [24] conducted a prospective observational study of 56 medical ICU patients in which plasma zinc levels, cytokine concentrations, and zinc transporter gene expression in peripheral blood monocytes were measured and correlated with illness severity. As zinc levels decreased, all cytokine levels increased significantly (IL-6 and IL-8 showing the strongest correlation). Plasma zinc levels were found to be low in critically ill patients and even lower in the septic patient group. Whereas no studies have demonstrated a significant difference in mortality or difference in length of stay with zinc supplementation, it continues to be included as a part of AOX regimens. Additionally, no data exist reporting optimal dosing or delivery of zinc supplementation [25] .
VITAMIN C (ASCORBIC ACID)
Adequate glutathione levels are required to maintain appropriate stores of vitamin C and vitamin E, co-factors important to the oxidant-antioxidant balance [7] . In specific states of increased oxidative stress such as in burns, severe trauma and critical illness, vitamin C may be required in high pharmacologic doses. While it is difficult to quantify deficits, high-dose vitamin C should be considered in patients with oxidative stress. Recommended daily allowances for vitamin C are 90 mg for men and 75 mg for women. In critically ill patients, normal levels of plasma vitamin C levels can be restored with intravenous dosing of 3 g/day of vitamin C. Parenteral administration is advocated over enteral dosing as a ceiling effect is encountered at 400 mg of daily oral administration [26] . High-dose intravenous vitamin C appears to be beneficial in burn patients and there are no confirmed adverse effects [27, 28] .
Tanaka et al. [28] performed a randomized trial in which patients received placebo or high-dose ascorbic acid (66 mg/h) during the first 24 h after thermal injury. The investigators noted that the treatment group had significantly lower resuscitation requirements, weight gain, and wound edema. Moreover, the authors noted a decrease in respiratory failure in the treatment arm.
N-ACETYL-CYSTINE
N-acetyl-cystine (NAC) serves as an AOX acting directly as a glutathione substitute and indirectly as a precursor for glutathione. NAC causes vasodilatation while inhibiting platelet aggregation, aiding in regeneration of endothelial-derived relaxing factor, and reducing IL-8 and TNF-a production [1] . Controversy exists in the actual utility of NAC in critically ill and injured patients. While some data suggest that NAC may decrease pulmonary morbidity, there is no significant difference in regards to ICU or hospital LOS and long-term mortality [1, 3, 8] . Whereas NAC has been shown to be in reduced amounts in the broncheo-alveloar lavage fluid in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) patients, supplementation has demonstrated no mortality benefit over placebo [29] . In fact, NAC may actually be associated with worsening sepsis and MODS [1] .
FATTY ACIDS
Fish oils, particularly v-3 fatty acids, have been shown to suppress excessive endothelial activity, decrease the production of proinflammatory mediators, and exert positive effects on pulmonary mechanics [5] . The anti-inflammatory properties of v-3 fatty acids appear to be related to their ability to displace arachidonic acid from cellular membranes as they compete with v-6 fatty acids [4, 6, 29] . Current data suggest fish oils may decrease the rate of mortality in ARDS patients with enteral supplementation. However, their impact on overall mortality and ICU and hospital LOS remains controversial [1, 4, 6] .
Animal models have demonstrated that v-3 fatty acids alter the inflammatory process following states such as hemorrhagic shock through significant reductions in nitric oxide synthetase levels and lung edema [30] . Building on this, the Investigating Nutritional Therapy with EPA, GLA and Antioxidants Role in Sepsis Treatment (INTERSEPT) Study Group conducted a prospective, randomized, control study of 106 patients fed a diet of eicosapentaenoic acid, g-linolenic acid, and AOX versus a control enteral diet [31 && ]. The study demonstrated that treatment patients developed less severe sepsis and/or septic shock compared to those receiving a control diet (26 versus 50%). In addition, treatment patients developed less cardiovascular and respiratory failure compared with controls and had reduced ICU LOS and overall costs. However, there was no effect on 28-day mortality.
COMBINATION THERAPY
With glutamine and arginine both being conditionally essential amino acids with inter-related functions, the question remains if combination administration is more advantageous over single nutrient supplementation. While the individual effects of glutamine and arginine are well documented, combination administration can be complex and unpredictable [32] . Since glutamine contributes to de-novo arginine synthesis, predicting if arginine will preferentially be used for nitric oxide synthesis or polyamines is difficult. Massive supplementation of arginine may have detrimental effects leading to promotion of inflammation, endothelial dysfunction, mucosal swelling, and epithelial damage. Combination of arginine and glutamine may be synergistic or the effects may be inhibitory or neutral.
Nathens et al. [33] previously demonstrated that early administration of high-dose antioxidants (vitamins C and E) could reduce infectious complications and organ dysfunction following injury and hemorrhagic shock (Table 1) . Building on this, investigators at Vanderbilt conducted a retrospective cohort study in severely injured patients, using a regimen of vitamin C (1000 mg) and vitamin E (1000 IU) every 8 h, as well as selenium (200 mcg) daily. Their high-dose AOX regimen was associated with a significant reduction in mortality (Table 1 ) [34] . In a follow-up study, Giladi et al. [35 && ] noted that whereas respiratory failure rates were significantly lower in the AOX treatment group, there was no difference in renal failure or SIRS (Table 1) . However, the AOX regimen was associated with a significant reduction in infections (surgical site infections, pneumonia, and catheter-related bloodstream infections) and abdominal wall complications (wound dehiscence, surgical site infections, and abdominal compartment syndrome). Moreover, the cost of this 7-day treatment was approximately $11.00 USD per patient.
In 2008, Berger et al. [36] reported their findings of a combination regimen administered to postoperative cardiac, major trauma, and subarachnoid hemorrhage patients (Table 1 ). Patients were randomized to receive either AOX supplement or placebo for 5 days starting within 24 h of admission. The AOX and micronutrient supplementation consisted of selenium, zinc, vitamin B 1, vitamin C, and a-tocopherol. The investigators noted that in the 66 trauma patients, those receiving AOX supplementation had shorter hospital stays compared with placebo. The study did not demonstrate a difference in mortality between AOX and placebo groups.
A recent meta-analysis of 18 randomized controlled trials examined the impact of AOX on endpoints such as mortality, infections complications, and LOS [37 && ]. In critically ill patients, there exists a potential benefit of micronutrient therapy with a suggested decrease in mortality without a significant difference in infections complications.
No difference was seen between enteral versus parenteral delivery. Selenium was the most commonly used single nutrient, yet there was great variability in the administration of combination micronutrients as well as dosages among the different studies. Compared to a review in 2005, this meta-analysis found only a small difference in mortality reduction with single nutrient supplementation, whereas combination micronutrient replacement had a much greater reduction in mortality [8,37 && ]. Finally, a recent study from the ARDS-Net investigators noted that combination therapy with fatty acids and AOX did not improve clinical outcomes in patients with ALI and may be harmful [38] . Rice et al. carried out a double-blind, randomized, multicenter trial of twice-daily enteral supplementation of v-3 fatty acids, linolenic acid, and AOX versus a standard iso-caloric enteral feeding. Unlike previous studies, the authors found no difference in ventilator-free days or infectious complications. Also, there was a trend (P ¼ 0.11) towards increased adjusted 60-day mortality in the treatment arm. Of note, unlike previous studies supporting fatty acid and AOX supplementation, patients in this study's treatment arm did not have significant reductions in inflammatory mediators compared to the control group. This, and other formulation and dosing differences, may explain the disparity in their findings.
ROUTES OF ADMINISTRATION
Advocates of immune-enhancing formulas in highrisk trauma patients recommend the enteral route of 
CONCLUSION
The role of AOX as pharmaconutrients in severely injured patients is conceptually appealing in combating oxidative stress with the potential to decrease mortality, reduce LOS, and decrease infection complications. Ideal dosing, route of administration, timing of administration, duration of therapy, and role of single versus combination supplementation still remain unclear. Additional placebo-controlled, multi-institutional, randomized controlled studies are needed to answer the above questions. To address this, the Reducing Deaths due to Oxidative Stress (The REDOXS Study) study is finalizing enrollment [40] . REDOXS is examining the impact of high-dose glutamine and/or AOX supplementation on 28-day mortality in 1200 mechanically ventilated, critically ill patients. Also, the group is examining the impact of enteral versus parenteral delivery of these AOX and micronutrients. The hope of the anticipated results of the REDOXS Study is to provide appropriately powered guidelines for the administration of AOX in the ICU. A prospective, randomized trial involving 150 critically ill patients with SIRS/sepsis and a SOFA score greater than 5. Patients were randomized patients to receive placebo or a high-dose selenium supplementation for a total course of 14 days. No difference was appreciated in mortality or markers of inflammation between the groups and selenium supplementation had no significant effects on major study endpoints. 
